CORT

Corcept Therapeutics Incorporated [CORT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CORT Stock Summary

Top 10 Correlated ETFs

CORT


Top 10 Correlated Stocks

CORT


In the News

11:20 28 Mar 2024 CORT

Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?

Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.

02:36 28 Mar 2024 CORT

Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow

Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.

09:50 28 Mar 2024 CORT

Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript

04:05 28 Mar 2024 CORT

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

01:11 28 Mar 2024 CORT

Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?

Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

12:02 28 Mar 2024 CORT

Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024

Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.

10:33 28 Mar 2024 CORT

Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

12:47 28 Mar 2024 CORT

Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva

The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.

11:32 28 Mar 2024 CORT

Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva

Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent infringement lawsuit filed against Teva Pharmaceuticals. A US District Court said Teva does not infringe any asserted claims of Corcept's US Patents 10,195,214 and 10,842,800, both of which concern methods of safely administering its flagship Korlym drug with drugs that are strong inhibitors of CYP3A4, an enzyme mainly found in the liver and the intestine.

11:17 28 Mar 2024 CORT

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

CORT Financial details

Company Rating
Strong Buy
Market Cap
2.54B
Income
106.14M
Revenue
482.38M
Book val./share
4.56
Cash/share
3.31
Dividend
-
Dividend %
-
Employees
352
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
28.02
Forward P/E
15.44
PEG
38.03
P/S
5.75
P/B
5.55
P/C
7.65
P/FCF
16.76
Quick Ratio
3.31
Current Ratio
3.54
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
1.02
EPS next Y
1.64
EPS next Q
0.23
EPS this Y
7.37%
EPS next Y
61.18%
EPS next 5Y
221.9%
EPS last 5Y
4.46%
Revenue last 5Y
9.5%
Revenue Q/Q
9.55%
EPS Q/Q
-6.45%
-
-
-
-
SMA20
6.39%
SMA50
-1.21%
SMA100
-10.66%
Inst Own
68.4%
Inst Trans
0.91%
ROA
15%
ROE
19%
ROC
0.21%
Gross Margin
99%
Oper. Margin
22%
Profit Margin
20%
Payout
-
Shs Outstand
103.52M
Shs Float
89.26M
-
-
-
-
Target Price
30
52W Range
20.87-34.28
52W High
-25.53%
52W Low
+26.6%
RSI
61.01
Rel Volume
0.46
Avg Volume
1.62M
Volume
746.17K
Perf Week
4.15%
Perf Month
9.85%
Perf Quarter
-2.24%
Perf Half Y
-21.66%
-
-
-
-
Beta
0.472
-
-
Volatility
0.32%, 0.81%
Prev Close
2.3%
Price
25.32
Change
1.77%

CORT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.512.852.913.474.32
Net income per share
0.770.850.890.870.95
Operating cash flow per share
1.111.221.331.041.14
Free cash flow per share
1.11.211.331.031.14
Cash per share
4.586.773.826.923.3
Book value per share
3.034.212.984.334.53
Tangible book value per share
3.034.212.984.334.53
Share holders equity per share
3.034.212.984.334.53
Interest debt per share
0.090.040.010.050
Market cap
1.48B3.25B2.49B2.36B3.63B
Enterprise value
1.17B2.77B2.16B1.92B3.49B
P/E ratio
15.7130.6522.1723.2234.19
Price to sales ratio
4.839.186.815.867.52
POCF ratio
10.8721.3814.8619.5728.57
PFCF ratio
10.9621.5514.919.6428.6
P/B Ratio
3.996.216.644.697.16
PTB ratio
3.996.216.644.697.16
EV to sales
3.817.845.94.787.24
Enterprise value over EBITDA
10.4721.6417.3417.0431.87
EV to operating cash flow
8.5818.2612.8615.9627.5
EV to free cash flow
8.6518.4112.8916.0127.53
Earnings yield
0.060.030.050.040.03
Free cash flow yield
0.090.050.070.050.03
Debt to equity
0.010.01000
Debt to assets
0.010.01000
Net debt to EBITDA
-2.79-3.7-2.69-3.87-1.23
Current ratio
8.5749.6755.216.114.39
Interest coverage
22.010031.670
Income quality
1.451.431.491.191.2
Dividend Yield
00.010.010.010
Payout ratio
0.070.20.130.240
Sales general and administrative to revenue
00000
Research and developement to revenue
0.290.320.310.330.38
Intangibles to total assets
-0.1-0.06-0.2600
Capex to operating cash flow
-0.01-0.01000
Capex to revenue
00000
Capex to depreciation
-0.5-0.55-0.15-0.14-0.06
Stock based compensation to revenue
0.10.090.120.110.1
Graham number
7.2597.749.239.84
ROIC
0.240.190.30.190.18
Return on tangible assets
0.210.170.210.170.17
Graham Net
4.446.633.686.582.67
Working capital
311.52M513.69M374.48M417.12M354.13M
Tangible asset value
410.53M559.53M488.08M501.84M506.71M
Net current asset value
311.52M475.85M333.44M417.12M343.82M
Invested capital
0.010.01000
Average receivables
18.76M23.06M26.91M36.34M50.09M
Average payables
7.9M9.05M8.73M9.44M14.69M
Average inventory
16.82M19.28M19.55M17.49M12.38M
Days sales outstanding
23.7327.0227.5540.9241.71
Days payables outstanding
499.82690.11477.45811.74979.72
Days of inventory on hand
1.15K1.38K1.24K1.15K435.34
Receivables turnover
15.3813.5113.258.928.75
Payables turnover
0.730.530.760.450.37
Inventory turnover
0.320.260.290.320.84
ROE
0.250.20.30.20.21
Capex per share
-0.01-0.01000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.890.941.081.111.22
Net income per share
0.140.140.250.280.28
Operating cash flow per share
0.290.230.390.480.05
Free cash flow per share
0.290.230.390.480.05
Cash per share
6.895.583.323.23.31
Book value per share
4.314.693.854.164.56
Tangible book value per share
4.314.693.854.164.56
Share holders equity per share
4.314.693.854.164.56
Interest debt per share
0.03-0.02000.03
Market cap
2.36B2.45B2.43B3.03B3.61B
Enterprise value
1.93B1.98B2.26B2.92B3.47B
P/E ratio
35.5838.522.1124.1228.77
Price to sales ratio
22.9323.1520.6824.4926.65
POCF ratio
70.7694.2257.5857.21612.99
PFCF ratio
70.8394.2257.7257.25612.99
P/B Ratio
4.714.625.776.567.12
PTB ratio
4.714.625.776.567.12
EV to sales
18.718.7519.2223.5925.65
Enterprise value over EBITDA
85.65133.3874.4193107.53
EV to operating cash flow
57.7276.3253.5155.1589.99
EV to free cash flow
57.7776.3253.6455.14589.99
Earnings yield
0.010.010.010.010.01
Free cash flow yield
0.010.010.020.020
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
-19.36-31.27-5.66-3.56-4.19
Current ratio
6.1120.954.653.544.39
Interest coverage
12.66-4.15008.84
Income quality
2.011.631.541.690.19
Dividend Yield
00000
Payout ratio
0.080.110.020.160.04
Sales general and administrative to revenue
00000
Research and developement to revenue
0.360.390.370.370.4
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.040-0.12-0.220
Stock based compensation to revenue
0.10.110.10.10.1
Graham number
3.723.854.675.145.38
ROIC
0.030.020.060.060.05
Return on tangible assets
0.030.030.050.050.05
Graham Net
6.565.182.732.372.69
Working capital
417.12M502.96M339.53M309.65M354.13M
Tangible asset value
501.84M529.58M421.61M461.68M506.71M
Net current asset value
417.12M439.92M329.58M299.18M343.82M
Invested capital
00000
Average receivables
37.24M45.81M46.56M47.59M51.87M
Average payables
10.08M11.6M9.6M12.34M17.05M
Average inventory
11.54M16.8M11.74M7.21M7.62M
Days sales outstanding
39.3539.6635.5935.4136.64
Days payables outstanding
728.27728.31456.06914.22834.12
Days of inventory on hand
1.04K1.08K395.39411.05370.64
Receivables turnover
2.292.272.532.542.46
Payables turnover
0.120.120.20.10.11
Inventory turnover
0.090.080.230.220.24
ROE
0.030.030.070.070.06
Capex per share
00000

CORT Frequently Asked Questions

What is Corcept Therapeutics Incorporated stock symbol ?

Corcept Therapeutics Incorporated is a US stock , located in Menlo park of Ca and trading under the symbol CORT

Is Corcept Therapeutics Incorporated buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $31.5. The lowest prediction is $30 and the highest is $33

What is CORT stock prediction ?

What is Corcept Therapeutics Incorporated stock quote today ?

Corcept Therapeutics Incorporated stock price is $25.32 today.

Is Corcept Therapeutics Incorporated stock public?

Yes, Corcept Therapeutics Incorporated is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks